Reviewer’s report

Title: Emergency Etoposide-Cisplatin (Em-EP) for patients with germ cell tumours (GCT) and trophoblastic neoplasia (TN)

Version: 0 Date: 29 May 2019

Reviewer: Christa Nagel

Reviewer’s report:

Overall great manuscript on an important subject matter.

On page 8 line 20 in results change commonest to most common.

On page 8 line 21 of results you state most patients received Em-EP at their initial diagnosis. How many received it for a recurrence?

In the clinical outcome section of the results you say that 2 patients died at less than 4 weeks and a total of 20 patients died with a 6 month minimal follow up. You may want to reference table 2 here for the causes of death. You may also want to break down the causes to within the first 4 weeks and within the initial 6 months.

On page 14 line 11 of the discussion you state that the mortality of induction chemotherapy with Em-EP with 99% of patients alive at 4 weeks. I recommend adding the mortality rate with standard chemotherapy regimens for comparison.

In the results you state 9% of patients developed neutropenic sepsis. This seems high and that consideration for prophylactic GCSF may be given to this patient population who is already compromised. You may want to discuss this further in the discussion section.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.
I agree to the open peer review policy of the journal